Introduction
Materials and Methods
Subjects and Study Design
Inclusion criteria |
Healthy male subjects |
Age between 20–55 years old |
Type: Caucasian race |
Subjects showing clinical signs of androgenetic alopecia type II–IV |
Subjects who have not used antihair loss treatments the 6 months before the study start |
Promise to not use topical and/or systemic products with similar effect to that one of the product to be tested throughout the study period |
Promise to not change the daily routine |
Exclusion criteria |
Subjects who do not fit the inclusion criteria |
Subjects with allergies or sensitivity to cosmetic products, toiletries, sunscreens and/or topical drugs |
Disorder of the scalp |
Subjects with dermatological problems on the test area |
Subjects under pharmacological treatment (both locally or systemically) |
Positive anamnesis for atopy |
Tested Product
Formulation A: test active ingredients | Formulation B: placebo control |
---|---|
Alcohol denat., aqua, glycerin, butylene glycol, lysine hydrochloride, benzyl nicotinate, acetyl cysteine, benzophenone-4, disodium EDTA, glycyrrhetinic acid, menthol, sodium hydroxide, silanediol salicylate, triethanolamine, serine, threonine, propylene glycol, adenosine, allantoin, zinc acetylmethionate, hematite extract, hydrolyzed rice protein, phosphatidylcholine, hydrolyzed soy protein, hydrolyzed DNA, hydrolyzed MA, Eriobotrya japonica leaf extract, salicylic acid, glycogen, glycoproteins, Artemia extract, C.I. 14720, C.I. 16255, C.I. 19140, C.I. 28440, C.I. 73015 | Alcohol denat., aqua, disodium EDTA, sodium hydroxide, C.I. 14720, C.I. 16255, C.I. 19140, C.I. 28440 |
Phototricogram
Pull Test
Global Photographic Assessment
Statistical Analysis
Results
Crescina® HFSC (n = 23) | Placebo (n = 23) | |
---|---|---|
Mean age ± SD, years | 34.7 ± 11.2 | |
Mean baseline anagen ratio ± SD | 63.8 ± 4.2% | 62.8 ± 4.3% |
Hamilton–Norwood score, no. (%) of individuals | ||
Type II | 5 (21.7) | 5 (21.7) |
Type III | 10 (43.5) | 11 (47.8) |
Type III vertex | 5 (21.7) | 4 (17.4) |
Type IV | 3 (13.0) | 3 (13.0) |
Anagen
Active product | Placebo product | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
n
| Mean (±SD) | 1st quartile | Median | 3rd quartile |
n
| Mean (±SD) | 1st quartile | Median | 3rd quartile | |
T = 0 months | 23 | 63.8 ± 4.2 | 62.4 | 64.3 | 67.4 | 23 | 62.8 ± 4.3 | 59.4 | 62.2 | 66.7 |
T = 2 months | 23 | 70.6 ± 6.9 | 65.8 | 69.1 | 76.9 | 23 | 63.7 ± 5.0 | 59.9 | 62.5 | 65.9 |
T = 4 months | 23 | 74.5 ± 5.6 | 69.8 | 73.9 | 77.7 | 23 | 65.0 ± 5.2 | 60.8 | 64.5 | 69.4 |
Pull Test
Active product | Placebo product | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
n
| Mean (±SD) | 1st quartile | Median | 3rd quartile |
n
| Mean (±SD) | 1st quartile | Median | 3rd quartile | |
T = 0 months | 19 | 9.2 ± 1.3 | 8 | 9 | 10 | 18 | 9.1 ± 1.8 | 8 | 9 | 10 |
T = 2 months | 19 | 6.4 ± 1.8 | 5 | 6 | 8 | 18 | 8.3 ± 2.1 | 7 | 8 | 10 |
T = 4 months | 19 | 4.8 ± 1.5 | 4 | 5 | 6 | 18 | 7.6 ± 1.9 | 6 | 8 | 9 |